Effects of the dienogest-containing oral contraceptive Valette® on skin and hair. Results of a postmarketing surveillance study

Drugs of Today

Volumn 35, Issue SUPPL. C, 1999, Pages 97-104

  Zimmermann, T ^a   Wisser, K H ^a   Dietrich, H ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; LOW DOSE ORAL CONTRACEPTIVE; UNCLASSIFIED DRUG;

ACNE VULGARIS; ADULT; AGE DISTRIBUTION; CHILD; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HAIR DISEASE; HUMAN; HYPERANDROGENISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; REVIEW; SKIN DISEASE;

EID: 0032775662     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Jones, E.E. Androgenic effects of oral contraception: Implications for patient compliance. Am J Med 1995, 98: 116S-19S.
2. Drife, J.O. The Benefits and Risks of Oral Contraceptives Today. 2nd ed. London: Parthenon 1996.
3. Elstein, M., Furniss, H. The fiction of an ideal contraceptive. Adv Contracept 1996, 12: 129-38.
4. Elstein, M. Present status of hormonal contraception (COCs). Adv Contracept 1996, 12: 155-66.
5. Taubert, H.D., Kuhl, H. Kontrazeption mit Hormonen. G. Thieme: Stuttgart 1995, 2. Aufl., 355-63.
6. Oettel, M., Carol, W., Elger, W., et al. A 19-norprogestin without a 17α-ethinyl group. II: Dienogest from a pharmacodynamic point of view. Drugs of Today 1995, 31: 517-36.
7. Oettel, M., Carol, W., Gräser, T. et al. Der Einfluß einer Ethinylestradiol-Dienogest-Kombination auf die Serum-Androgen-Konzentrationen. Zentralbl Gynäkol 1997, 119: 597-606.
8. Moore, C., Feichtinger, W., Klinger, G. et al. Clinical findings with the dienogest-containing oral contraceptive Valette®. Drugs of Today 1999, 35(Suppl. C): 53-68.
9. Luderschmidt, C. Hormonal control of androgenic disorders in women. In: Extragenital Effects of Oral Contraceptives. Elstein, M., (Ed.). The Parthenon Publishing Group: Carnforth 1997, 45-51.
10. Moore, C., Luderschmidt, C., Moltz, L., Oettel, M., Schreiber, G. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette®. Drugs of Today 1999, 35(Suppl. C): 69-78.
11. Zimmermann, T., Dietrich, H., Wisser, K.H., Hoffmann, H. Efficacy and tolerability of the dienogest-containing oral contraceptive Valette®. Results of a post-marketing surveillance study. Drugs of Today 1999, 35(Suppl. C): 79-87
12. Serfaty, D. Medical aspects of oral contraceptive discontinuation. Adv Contracept 1992, 8 Suppl. 1: 21-33.
13. Bilotta, P., Favilli, S. Clinical evaluation of a monophasic ethinyl estradiol desogestrel-containing oral contraceptive. Arzneimittelforschung 1988, 38: 932-4.
14. Weber-Diehl, F., Unger, R., Lachnit, U. Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial. Contraception 1992, 46: 19-27.